EIF4E-IN-6

• Description :

  EIF4E-IN-6 (compound 4b) is a GMP analogs synthesized to targeteIF4Eand restrain its binding to cap mRNA.eIF4E-IN-6shows cell cytotoxicity against Caco-2, HepG-2, and MCF-7 cells, withIC50values of 31, 27, and 21 μM, respectively[1].

• UNSPSC :

  12352005

• Target :

  Eukaryotic Initiation Factor (eIF)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/eif4e-in-6.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1NC(NC(C2=CC=CC=C2)=O)=NC3=C1[N+](CC4=CC=CC=C4)=CN3C5OC(COP(NNC6=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C6)(O[Na])=O)C7C5OC(C)(C)O7.[Br-]

• Molecular Formula :

  C33H32BrN9NaO12P

• Molecular Weight :

  880.53

• References & Citations :

  [1]Attia RT, et al. Newly Synthesized Anticancer Purine Derivatives Inhibiting p-EIF4E Using Surface-Modified Lipid Nanovesicles. ACS Omega. 2023;8 (41) :37864-37881. Published 2023 Oct 6.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported